Clinical Trial

A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work

Study acronym: MOBILIZE
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate efficacy of riliprubart compared to placebo in adult participants with CIDP whose disease is refractory to standard of care. The study duration will be for a maximum of 111 weeks including screening, treatment phases, and follow-up.
Protocol Amendment History 2 changes
notable Trial sites expanded: 128 -> 131 locations 2026-06-13
notable Trial sites expanded: 125 -> 128 locations 2026-05-27
Trial Details
NCT Number NCT06290128
Lead Sponsor Sanofi
Conditions Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic
Enrollment 140 participants
Start Date 2024-07-12
Primary Completion 2027-05-17 (estimated)
Study Completion 2028-11-20 (estimated)
Updated on ClinicalTrials.gov 2026-06-12